Previous 10 | Next 10 |
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that NASDAQ has halted trading of the Company’s common stock. As per the U.S. Food and Drug Administration (FDA) guidelines for new molecular entities (NMEs), the FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) is...
In 1992, Congress passed the Prescription Drug User Fee Act (PDUFA) allowing the U.S. Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the drug review and approval process. To promote getting novel medicines to patients expeditiously, the act requires the FDA to...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38 th Annual J.P. Morgan Healthcare Conference. Timothy Walbert, chairman, president and chief executive officer will present at 5 p.m. PT on Jan. 15, 2020. The conference presentation will b...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
Horizon Therapeutics plc (Nasdaq: HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as ...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the launch of “Listen to Your Eyes,” a new website and Facebook community designed to provide education and support for people who are living with thyroid eye disease (TED) – a rare, serious, progressive and visi...
Horizon Therapeutics plc (NASDAQ: HZNP) announced today that it has been named to FORTUNE Magazine’s 2019 “Best Workplaces for Parents” list , which highlights companies that best support employees, regardless of parenting status, as well as offer quality benefits incl...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following upcoming conferences: Stifel 2019 Healthcare Conference Date: Tuesday, Nov. 19, 2019 Presentation Time: 9:45 a.m. EST Location: New York Jefferies 2019 Lond...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2019 Q3 earnings Read more ...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...